OPKO Health Q4 EPS Surprises 39.4%; Service Revenue Drops 31%
OPKO Health reported Q4 revenue of $148.5 million, down 19.1% year-over-year yet 7.6% above consensus estimates, and non-GAAP EPS of −$0.04, beating forecasts by 39.4%. Product revenue climbed 16.8% to $43.7 million while service revenue plunged 31% and IP transfer sales declined 21.8% year-over-year.
1. Q4 Financial Performance
For the quarter ended December 2025, OPKO Health generated $148.5 million in revenue, down 19.1% from a year ago but 7.6% above the consensus estimate of $138.1 million. Adjusted EPS was a loss of $0.04, outperforming the forecasted loss of $0.07 by 39.4% and reversing a year-ago EPS of $0.01.
2. Revenue Segment Breakdown
Service revenues fell 31% year-over-year to $71.1 million, missing the $72.4 million estimate, while intellectual property and other revenues declined 21.8% to $33.7 million versus a $24.4 million projection. Product sales rose 16.8% to $43.7 million, topping the $41.3 million consensus and reflecting continued strength in the company’s core offerings.
3. Market Reaction and Outlook
Shares have lost 7.8% over the past month and trade with a Hold rating, reflecting mixed investor sentiment after the beat-and-miss results. Consensus for the coming quarter calls for a $0.06 EPS loss on $131.0 million revenue, and full-year projections stand at a $0.24 loss on $565.9 million, while the medical instruments industry remains in the top 30% of peers.